Protagenic SEC Filings

Protagenic Therapeutics, Inc. (PTIXW) amended a material event report to disclose near-term clinical milestones for its oncology candidate PT00114 and filing of transaction-related pro forma financials. The company expects to complete the multiple-dose portion of the Phase I study for PT00114 and make those results publicly available in Q2 FY2026 (quarter ending September 30, 2025). It also anticipates initiating a Phase IIa study for PT00114 in Q4 FY2026 (quarter ending March 31, 2026). The unaudited pro forma combined statement of operations for the year ended March 31, 2025, related to the described transaction, is filed as Exhibit 99.2 to this Form 8-K/A and is incorporated by reference.

Protagenic Therapeutics, Inc. (PTIXW) received a Schedule 13G/A filed by Bigger Capital Fund, LP; Bigger Capital Fund GP, LLC; and Michael Bigger reporting their relationship to the issuer's Common Stock (CUSIP 74365N202). The filing states that as of August 22, 2025, each Reporting Person owned no shares of the issuer and reported 0% ownership. The filing includes addresses and citizenship information for each Reporting Person and certifications that the securities were not acquired to influence control of the issuer. Signatures executed by Michael Bigger certify the accuracy of the statement.

Protagenic Therapeutics approved a focused restructuring to transition to a virtual operating model and concentrate capital on its lead clinical asset, PT00114. The Board expects this plan to reduce annualized operating expenses by approximately $8 million while pausing preclinical programs (PHYX-001 through PHYX-005) to pursue partnerships or out-licensing and conserve cash for the Phase 2 trial. The Company currently expects the Phase 2 for PT00114 to complete in approximately 9 to 12 months, subject to enrollment and customary factors.

The plan eliminates certain executive roles by terminating the employment of the CEO and COO, who remain on the Board, and reduces headcount primarily tied to preclinical, regulatory, and IP functions. The Company expects one-time charges related to the restructuring but cannot yet estimate amounts or timing. The Company also changed its fiscal year-end to March 31.